#PRESS : Product recommended for approval for the treatment of diabetes by the European regulatory authorities

#PRESS : Novo Nordisk product approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease

#PRESS : Highlights to be presented at Novo Nordisk’s Capital Markets Day 2024

#PRESS : Novo Nordisk molecule demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in trial

#PRESS Notice for the Annual General Meeting of Novo Nordisk A/S on Thursday 21 March 2024 at 14.00 (CET)

#PRESS Novo Nordisk to acquire three fill-finish sites from Novo Holdings A/S in connection with the Catalent, Inc. transaction

#PRESS Novo Nordisk's sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion in 2023

#PRESS Phase 3a trial successfully completed with once-weekly product demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment in people with type 2 diabetes

#PRESS Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases

#PRESS Novo Nordisk invests more than 16 billion Danish kroner in expansion of production facilities in Chartres, France

#PRESS : Novo Nordisk product cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine.

#PRESS : Novo Nordisk invests more than 42 billion Danish kroner in expansion of manufacturing facilities in Kalundborg, Denmark

#PRESS : Novo Nordisk's sales increased by 29% in Danish kroner and by 33% at constant exchange rates to DKK 166.4 billion in the first nine months of 2023

#PRESS : Novo Nordisk to acquire molecule for uncontrolled hypertension from KBP Biosciences

#PRESS Novo Nordisk raises sales and operating profit outlook for 2023

#PRESS Novo Nordisk will stop the kidney outcomes trial, FLOW, based on interim analysis

#PRESS Valo Health and Novo Nordisk to collaborate to discover and develop novel treatments for cardiometabolic diseases using human data and artificial intelligence

#PRESS Novo Nordisk and UNICEF to extend joint initiative to prevent global childhood obesity

I thank Novo Nordisk and Aspen Pharmacare for your commitment to expand access to affordable human #insulin in Africa.

This is a significant milestone in our collective work to make #diabetes treatment and care accessible to those who need it the most, in Africa and around the…